<DOC>
	<DOCNO>NCT01841021</DOCNO>
	<brief_summary>The main purpose study test brentuximab vedotin effect cancer patient certain type large B-cell lymphoma . The side effect ( unwanted effect ) SGN-35 patient certain type large B-cell lymphoma also study . It known brentuximab vedotin well worse treatment patient might give .</brief_summary>
	<brief_title>Pilot Study Brentuximab Vedotin Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis PTCL express CD30 receptor . Following PTCL subtypes eligible : Peripheral T cell lymphoma , otherwise specify ( NOS ) ; Angioimmunoblastic Tcell Lymphoma ; Subcutaneous Panniculitis Like Tcell Lymphoma ; Hepatosplenic gamma/delta T cell Lymphoma ; Extranodal natural killer ( NK ) Tcell Lymphoma , nasal type ; Enteropathyassociated Tcell lymphoma ; Adult Tcell Leukemia/lymphoma ; Tcell prolymphocytic leukemia ; Primary cutaneous gammadelta Tcell lymphoma ; Aggressive NK cell leukemia ; Aggressive subtype T cell Large Granular Lymphocytic ( LGL ) transform LGL leukemia ; Epstein Barr Virus ( EBV ) positive Tcell lymphoproliferative disorder childhood ; Transformed mycosis fungoides progress follow treatment least one systemic therapy ; Sezary syndrome Histology slide pathology material must available site patient enrollment order send Leading Institution study central pathology review pharmacodynamic study . Patients must progressive , relapsed refractory disease : At least one prior systemic antilymphoma regimen ( chemotherapy immunotherapy except transformed mycosis fungoides describe previously ) ; Relapsed fail autologous allogeneic stem cell transplant . Understand voluntarily sign Institutional Review Board ( IRB ) approve informed consent form Must least one site disease ( index lesion ) measurable two dimension compute tomography ( CT ) Patients leukemic form PTCL measurable lesion two dimension CT scan , relapsed refractory disease must detect immunohistochemistry flow cytometry molecular clonality study bone marrow peripheral blood . At least 2 week since last chemotherapy , radiation therapy , immunotherapy investigational product Must meet follow criterion within 4 day first dose study drug : Neutrophils ≥1,000/ul Hemoglobin ≥ 8 g/dL Platelets≥ 50.0x10^9 /L Total bilirubin ≤ 1.5 x upper normal limit , ≤ 5 x upper normal limit document hepatic involvement lymphoma history Gilbert 's Syndrome Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x upper normal limit ( ≤ 5 x upper normal limit document hepatic involvement lymphoma ) Calculated creatinine clearance ≥ 40 mL/min/1.73 m^2 base Cockcroft Gault method PT International Normalization Ratio ( INR ) , Activated Partial Thromboplastin Time ( APTT ) ≤ 1.5 x upper limit normal unless patient receiving anticoagulant . If patient anticoagulation therapy , level within therapeutic range . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Negative pregnancy test woman childbearing potential Recovered ( ≤ Grade 1 toxicity ) reversible effect prior antineoplastic therapy Any follow cardiovascular condition value within 6 month first dose study drug : Myocardial infarction New York Heart Association ( NYHA ) Class III IV heart failure History another primary malignancy clinical remission ; except adequately treated patient completely resect situ carcinoma , nonmelanoma skin cancer cervical carcinoma situ biopsy squamous intraepithelial lesion Pap smear , localized prostate cancer prostatespecific antigen ( PSA ) &lt; 1 ng/ml Known active cerebral/meningeal involvement lymphoma . Asymptomatic patient previously treat resolved central nervous system ( CNS ) lymphoma involvement permit . Prior administration Brentuximab vedotin Corticosteroid monotherapy lymphoma within 1 week first dose study drug Any serious underlying medical condition , opinion investigator medical monitor , would impair ability receive tolerate plan treatment Known hypersensitivity recombinant protein , component contain drug formulation Female patient lactate positive serum pregnancy test screening period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Peripheral T-Cell Lymphoma ( PTCL )</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>CD30 Receptor</keyword>
	<keyword>Large B-Cell Lymphoma</keyword>
</DOC>